In section Releases

Edge Delta Unveils Prod Immune System and AI SRE Performance Benchmark

Eighteen out of 21 production incidents were identified autonomously by Edge Delta’s new telemetry-native AI system during its inaugural benchmark test. By processing data directly within the telemetry pipeline rather than relying on external observability tools, the company aims to move beyond reactive alerting toward proactive production management.

Edge Delta Unveils Prod Immune System and AI SRE Performance Benchmark

Edge Delta has launched its "prod immune system," an AI-driven site reliability engineering platform that monitors production environments by analyzing logs, metrics, and traces as they stream. Unlike traditional agents that query dashboards after an alert triggers, this system functions continuously. It detects anomalies early, investigates them using real-time context, and suggests fixes through pre-configured approval workflows.

To standardize performance evaluation, the company introduced the AI SRE Arena. This open-source benchmark injects 21 distinct faults into a Kubernetes-based application to measure how effectively AI models diagnose issues. In initial tests, Edge Delta’s platform successfully caught 18 incidents, significantly outperforming a competing product that detected 12. The benchmark results, including scoring rubrics and answer keys, are now available for teams to run independently.

CEO Ozan Unlu emphasized that the shift allows agents to handle investigation tasks that previously required manual intervention. The platform incorporates new features such as "Loops," which maintain system health checks between incidents, and "Guardrails" to define the scope of autonomous actions. The service is currently available with a 14-day trial, while the technical documentation and comparison methodology remain open to the public.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!